Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.63 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | F2R | P25116 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400490 | 0.86 | KMT2A (0.57) | KCNK3KCNK9SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL2894248 | 0.86 | HTT (0.72) | KCNK3KCNK9SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL11668137 | 0.85 | KCNK3 (0.84) | KCNK3KCNK9SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12099694 | 0.84 | P2RX1 (0.71) | SMN1; SMN2HPGDKMT2AMEN1RAB9A | |
| SCHEMBL13927148 | 0.84 | HTT (0.74) | KCNK3KCNK9ALDH1A1KMT2AMEN1 | |
| SCHEMBL836637 | 0.84 | HPGD (0.68) | KCNK3KCNK9SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13023055 | 0.82 | MEN1 (0.63) | KCNK3KCNK9SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL533767 | 0.80 | KCNK3 (0.81) | KCNK3KCNK9SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13927048 | 0.79 | MEN1 (0.63) | KCNK3KCNK9ALDH1A1KMT2AMEN1 | |
| SCHEMBL10352150 | 0.79 | MEN1 (0.63) | KCNK3KCNK9ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2010078393-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KCNK3 1769/4885KCNK9 2468/4885SMN1; SMN2 4781/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KCNK3 1769/4885KCNK9 2468/4885SMN1; SMN2 4781/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KCNK3 1769/4885KCNK9 2468/4885SMN1; SMN2 4781/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | KCNK3 2395/4885KCNK9 4034/4885SMN1; SMN2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.